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Abstract
Objective We tested whether bedside testing for H-FABP
is, alone or integrated in combination models, useful for
rapid risk stratification of non-high-risk PE.
Methods We prospectively studied 136 normotensive
patients with confirmed PE. H-FABP was determined using
a qualitative bedside-test showing a positive result for
plasma concentration [7 ng/ml.
Results Overall, 11 patients (8.1 %) had an adverse
30-day outcome. Of 58 patients (42.6 %) with a positive
H-FABP bedside-test, 9 (15.5 %) had an unfavourable
course compared to 2 of 78 patients (2.6 %) with a nega-
tive test result (p = 0.009). Logistic regression analysis
indicated a sevenfold increased risk for an adverse outcome
(95 % CI, 1.45–33.67; p = 0.016) for patients with a
positive H-FABP bedside-test. Additive prognostic infor-
mation were obtained by a novel score including the
H-FABP bedside-test (1.5 points), tachycardia (2 points),
and syncope (1.5 points) (OR 11.57 [2.38–56.24];
p = 0.002 for C3 points). Increasing points were associ-
ated with a continuous exponential increase in the rate of
an adverse 30-day outcome (0 % for patients with 0 points
and 44.4 % for C5 points). Notably, this simple score
provided similar prognostic value as the combination of
the H-FABP bedside-test with echocardiographic signs of
right ventricular dysfunction (OR 12.73 [2.51–64.43];
p = 0.002).
Conclusions Bedside testing for H-FABP appears a use-
ful tool for immediate risk stratification of non-high-risk
patients with acute PE, who may be at increased risk of an
adverse outcome, in particular if integrated in a novel score
without the need of echocardiographic examination.
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Introduction
Acute pulmonary embolism (PE) is a frequent and life-
threatening disease. As proposed by current guidelines
[1, 2], risk stratification is based on clinical assessment of
haemodynamic instability in order to identify patients who
are at high risk of early death or life-threatening compli-
cations. Furthermore, laboratory biomarkers and imaging
procedures can be used for the assessment of right ven-
tricular (RV) dysfunction and injury and thus for classi-
fying non-high-risk patients into an intermediate-risk and a
low-risk subgroup. Currently, the most widely used labo-
ratory markers of myocardial (RV) dysfunction and injury,
natriuretic peptides [3] and cardiac troponins [4, 5], are
characterised by low specificity and positive predictive
values and do not, by themselves, justify more aggressive
treatment regimens [6]. Therefore, in the past years, strat-
egies for optimising risk stratification of normotensive
patients with acute PE have focused on (1) combination
models integrating information from laboratory markers
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and imaging procedures [7–9]; (2) clinical scores of PE
severity [10–14]; and (3) novel, promising biomarkers
[9, 15].
Recently, we and others demonstrated that heart-type
fatty acid-binding protein (H-FABP), an early and sensitive
marker of myocardial injury with favourable release
kinetics [16], is of prognostic value in patients with acute
PE and improves risk stratification of both, unselected
[17, 18] and haemodynamic stable patients [19]. In fact,
H-FABP appeared superior to cardiac troponins and
natriuretic peptides for predicting an adverse outcome [19].
In those studies, H-FABP concentrations were determined
using quantitative solid-phase enzyme-linked immunoad-
sorbent assays based on the sandwich principle (ELISAs)
which are currently not available for application in clinical
routine. Therefore, a point-of-care test for H-FABP was
developed that allows rapid (within 20 min) qualitative
determination of H-FABP concentrations in full blood or
plasma [20]. This assay emerged as a reliable test for the
early diagnosis of acute myocardial infarction [21, 22]. In
intermediate-risk patients with acute PE, positive test
results indicating H-FABP plasma concentrations above
7 ng/ml were associated with impaired RV function [23].
The aim of the present study was to determine whether
bedside testing of H-FABP is—alone or integrated in
combination models with other predictors of an adverse
outcome—capable of accelerating and simplifying risk
stratification of non-high-risk PE.
Methods
Patient population and study design
Consecutive patients who were diagnosed with acute
symptomatic PE were prospectively studied at the Uni-
versity of Go¨ttingen between October 2005 and April 2009.
For inclusion in the study, diagnosis of PE had to be
confirmed by an imaging procedure (contrast-enhanced
multidetector computed tomography, ventilation–perfusion
lung scan, or pulmonary angiography; or by echocardiog-
raphy showing the presence of mobile thrombi in the right
atrium or ventricle, or in the proximal portions of the
pulmonary artery) based on the diagnostic algorithms
proposed by recent guidelines [1, 2] and those existing
before 2008 [24, 25]. Patients were excluded from the
study if they met at least one of the following criteria: (1)
haemodynamic instability at presentation, defined as the
presence of the following: need for cardiopulmonary
resuscitation, systolic blood pressure \90 mmHg or drop
of systolic blood pressure by C40 mmHg for C15 min with
signs of end-organ hypoperfusion, or need for catechol-
amine administration to maintain adequate organ perfusion
and a systolic blood pressure C90 mm Hg; (2) PE being an
accidental finding obtained during diagnostic workup for
another suspected disease; and (3) denial of consent or
withdrawal of previously given consent for participation in
the study.
According to the study protocol, and as described pre-
viously [15, 19], complete data on baseline clinical, hae-
modynamic, and laboratory parameters were obtained
using a standardised questionnaire. Treatment decisions
were made by the physicians caring for the patient
according to the mentioned guidelines and not influenced
by the study protocol. Study results were not communi-
cated to the clinicians and thus not used to guide the
patient’s management or to monitor the effects of treatment
during the hospital stay or at any time during the 30-day
follow-up period.
A transthoracic echocardiogram was strongly recom-
mended by the study protocol. Right ventricular (RV)
dysfunction was defined as dilatation of the right ventricle
(end-diastolic diameter[30 mm from the parasternal view,
or a right/left ventricle diameter ratio C1.0 from the sub-
costal or apical view) combined with absence of inspiratory
collapse of the inferior vena cava, in the absence of left
ventricular or mitral valve disease [15, 19, 26].
Thirty-day clinical follow-up data were obtained from
all patients included in the study. An adverse 30-day out-
come was defined as death from any cause or at least one of
the following major complications [15, 19]: (1) need for
intravenous catecholamine administration (except for
dopamine at a rate of B5 lg/kg/min) to maintain adequate
tissue perfusion and prevent or treat cardiogenic shock; (2)
endotracheal intubation; and (3) cardiopulmonary resusci-
tation. The causes of death were adjudicated by two of the
authors (M.L. and C.D.) by reviewing the patients’ medical
records and the results of autopsy if performed.
The study protocol was approved by the Ethical Com-
mittee of the University of Go¨ttingen.
Laboratory parameters and biomarker testing
Venous plasma samples were collected on admission and
immediately stored at -80 C. Samples were later ana-
lysed in batches after a single thaw.
Qualitative plasma concentrations of H-FABP were
determined using a rapid chromatographic immunoassay
(‘‘bedside-test’’; CardioDetect lab, Rennessens GmbH,
Berlin, Germany), as previously described [20, 21]. The
test, which is approved for plasma, serum and whole blood
samples, shows a ‘‘positive’’ test result for H-FABP plasma
concentrations above 7 ng/ml, and test results are available
within 20 min.
Routine laboratory parameter measurements including
the conventional assays for cardiac troponin T (cTnT) and
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N-terminal pro-brain natriuretic peptide (NT-proBNP)
(quantitative electrochemiluminescence immunoassays
(Elecsys 1010/2010 analyzer, Roche Diagnostics, Mann-
heim, Germany) were performed at the Department of
Clinical Chemistry of the University of Go¨ttingen. For NT-
proBNP, a concentration of 1,000 pg/ml was defined as
cut-off value for distinguishing between normal and ele-
vated plasma levels [7, 15], and for cTnT a concentration
of 0.03 ng/ml as specified by the manufacturer. The glo-
merular filtration rate (GFR) was estimated using the
Modification of Diet in Renal Disease (MDRD) study
equation; renal insufficiency was defined as GFR \60 ml/
min/1.73 m2 body-surface area.
Statistical analysis
Continuous variables were found not to follow a normal
distribution as tested with the modified Kolmogorov–
Smirnov test (Lilliefors test). They were therefore expressed
as medians with corresponding 25th and 75th percentiles
and compared using the unpaired Mann–Whitney U test.
Categorical variables were compared using Fisher’s exact
test or Chi2 test, as appropriate. Receiver operating char-
acteristic (ROC) analysis was used to determine the area
under the curve (AUC) of baseline biomarker concentra-
tions and the novel score with regard to an adverse 30-day
outcome. Furthermore, ROC analysis was used for defining
the optimal cut-off value of the novel score. Sensitivity,
specificity, and the positive and negative predictive value
of elevated biomarker levels and the novel score were
calculated. The prognostic relevance of a positive H-FABP
bedside-test, elevated biomarker concentrations, and other
baseline parameters (as listed in Table 1) as well as of the
combination models with regard to 30-day outcome was
estimated using logistic regression analysis. Odds ratios
(OR) and the corresponding 95 % confidence intervals (CI)
were calculated.
All tests were two-sided and used a significance level of
0.05. Analyses were performed using the PASW software
(version 18.0, Chicago, Illinois, USA).
Results
Baseline clinical and laboratory findings
Overall, 136 normotensive patients with acute PE were
included in the study (derivation cohort). The baseline
clinical characteristics of the study patients are summarised
in Table 1. Diagnosis of PE was confirmed by contrast-
enhanced multidetector computed tomography (n = 120,
88.2 %), ventilation–perfusion lung scan (n = 13, 9.6 %),
or pulmonary angiography (n = 1; 0.7 %). In two patients
(1.5 %), the diagnosis of PE was established by echocar-
diographic criteria (as explained in the ‘‘Methods’’).
Overall, a transthoracic echocardiogram was performed in
102 patients (75.0 %); of these, 48 patients (47.1 %) were
diagnosed with RV dysfunction.
On admission, the H-FABP bedside-test was positive in
58 patients (42.6 %). As shown in Table 1, patients with a
positive H-FABP bedside-test were older and more fre-
quently diagnosed with congestive heart failure and renal
insufficiency. These patients were more likely to present
with syncope but less likely to present with chest pain.
Cardiac TnT levels ranged from 0.01 to 0.34 ng/ml with a
median value of 0.01 (25th to 75th percentile, 0.01–0.05)
ng/ml, and 47 patients (35.6 %) had cTnT levels above the
cut-off value of 0.03 ng/ml. NT-proBNP levels ranged
from 10 to 32,156 pg/ml with a median value of 766
(126–2,371) pg/ml, and 64 patients (47.4 %) had NT-
proBNP levels above the cut-off value of 1,000 pg/ml.
Both biomarkers were higher in patients with a positive
H-FABP bedside-test (p \ 0.001 each).
H-FABP bedside testing for predicting early outcome
after acute PE
During the acute phase of PE (first 30 days), 11 patients
(8.1 %) had an adverse outcome. Overall, 7 patients
(5.1 %) died; four deaths were due to PE and three to
cancer as the underlying disease. Patients with an adverse
30-day outcome presented more often with a positive
H-FABP bedside-test on admission compared to patients
with a favourable course (81.8 vs. 39.2 %; p = 0.009). As
shown in Table 2, a positive H-FABP bedside-test alone
was associated with a prognostic sensitivity (82 %) and
specificity (61 %). Overall, 15.5 % of the patients with a
positive H-FABP bedside-test on admission died or
developed life-threatening complications, while 2.6 % of
those patients with a negative test had an adverse 30-day
outcome. ROC analysis showed an AUC of 0.713 (95 %
CI, 0.567–0.859) for the H-FABP bedside-test, compared
to 0.654 (0.515–0.792) for cTnT and 0.639 (0.479–0.800)
for NT-proBNP.
Univariable logistic regression analysis indicated a
sevenfold increase in the risk of an adverse 30-day out-
come (95 % CI, 1.45–33.67; p = 0.016) for patients with a
positive H-FABP bedside-test. As shown in Table 3,
besides a positive H-FABP bedside-test, tachycardia, evi-
dence of RV dysfunction on echocardiography, and syn-
cope were identified as being univariably correlated with a
poor outcome, whereas elevation of the established bio-
markers cTnT (p = 0.432) and NT-proBNP (p = 0.094)
above their cut-off values did not appear to provide prog-
nostic information.
Clin Res Cardiol (2013) 102:73–80 75
123
Integration of the H-FABP bedside-test
into combination models
We investigated whether the combination of the H-FABP
bedside-test with other predictors of an adverse outcome
might further improve risk stratification of acute PE.
Indeed, the combination of the H-FABP bedside-test with
evidence of RV dysfunction on echocardiography was
associated with a 12.73-fold increase in the risk of an
adverse 30-day outcome (2.51–64.43; p = 0.002), which
appeared superior to the prognostic information provided
by the H-FABP bedside-test alone (Table 3). Of the
102 patients with an echocardiographic examination on
admission, 30 patients (29.4 %) had a positive H-FABP
bedside-test and evidence of RV dysfunction on echocar-
diography and 8 of them (26.7 %) had an adverse 30-day
outcome. On the other hand, two of 72 patients (2.8 %)
with a negative H-FABP bedside-test and/or a normal
echocardiogram died or had serious complications
(p = 0.001). Overall, the combination model was associ-
ated with a prognostic sensitivity of 80 %, a specificity of
76 %, a positive predictive value (PPV) of 27 %, and a
negative predictive value (NPV) of 97 %. In comparison,
neither cTnT nor NT-proBNP improved the prognostic
information provided by echocardiography alone (data not
shown).









Gender (male/female) 56 (41 %)/80 (59 %) 34 (44 %)/44 (56 %) 22 (38 %)/36 (62 %) 0.598
Age (years) 68 (56–76) 65 (48–71) 73 (63–80) \0.001
Symptoms on admission
Symptom onset \24 h 82 (60.3 %) 42 (53.8 %) 40 (67.0 %) 0.080
Tachycardia (heart rate C100 bpm) 53 (39.0 %) 25 (32.1 %) 28 (48.3 %) 0.075
Dyspnea 110 (80.9 %) 64 (82.1 %) 46 (79.3 %) 0.826
Chest pain 69 (50.7 %) 46 (59.0 %) 23 (39.7 %) 0.037
Syncope 30 (22.1 %) 10 (12.8 %) 20 (34.5 %) 0.003
Comorbidities and risk factors for VTE
History of DVT or PE 42 (30.1 %) 27 (34.6 %) 15 (25.9 %) 0.349
Immobilisation 49 (36.0 %) 28 (35.9 %) 21 (36.2 %) 1.000
Cancer 26 (19.1 %) 11 (14.1 %) 15 (25.9 %) 0.122
Congestive heart failure 14 (10.3 %) 4 (5.1 %) 10 (17.2 %) 0.042
Coronary artery disease 17 (12.5 %) 8 (10.3 %) 9 (15.5 %) 0.435
Chronic pulmonary disease 20 (14.7 %) 12 (15.4 %) 8 (13.8 %) 1.000
Laboratory parameters and biomarkers
Creatinine (mg/dl) 0.89 (0.71–1.10) 0.80 (0.70–1.00) 1.00 (0.80–1.30) \0.001
GFR \60 ml/min/1.73 m2 36 (26.5 %) 12 (15.4 %) 24 (41.4 %) 0.001
NT-proBNP (pg/ml) 766 (126–2,371) 309 (82–1,255) 1,605 (343–4,325) \0.001
NT-proBNP C1,000 pg/ml 64 (47.4 %) (n = 135) 28 (36.4 %) (n = 77) 36 (62.1 %) 0.005
cTnT (ng/ml) 0.01 (0.01–0.05) 0.01 (0.01–0.02) 0.03 (0.01–0.06) \0.001
cTnT C0.03 ng/ml 47 (35.6 %) 19 (24.4 %) 28 (48.3 %) 0.006
RV dysfunction 48 (47.1 %) (n = 102) 18 (32.7 %) (n = 55) 30 (63.8 %) (n = 47) 0.003
Patients were stratified according to a negative or positive H-FABP bedside-test on admission. Data are presented as absolute numbers
(percentages) or medians (25th to 75th percentile)
n number of patients with available data, Bpm beats per minute, VTE venous thromboembolism, DVT deep vein thrombosis, PE pulmonary
embolism, GFR glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, cTnT cardiac troponin T, RV right ventricular
Table 2 Receiver operating characteristics analysis for the predictive
value of biomarkers in acute normotensive pulmonary embolism
Sensitivity Specificity PPV NPV
H-FABP bedside-test
positive
0.82 0.61 0.16 0.97
cTnT C0.03 ng/ml 0.45 0.66 0.11 0.93
NT-proBNP C1,000 pg/ml 0.73 0.55 0.13 0.96
PPV positive predictive value, NPV negative predictive value,
H-FABP heart-type fatty acid-binding protein, cTnT cardiac troponin
T, NT-proBNP N-terminal pro-brain natriuretic peptide
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Since echocardiography may not be available on a
round-the-clock basis in many hospitals, and in view of the
fact that echocardiographic criteria for the detection of
acute RV dysfunction are often vague and poorly stand-
ardised [26, 27], we tested whether comparable prognostic
information could be obtained by an alternative combina-
tion model based on bedside parameters for rapid risk
assessment. For this purpose, all clinical variables that
were identified as univariable predictors of an adverse
30-day outcome (Table 3) were included in a score and the
respective weight was obtained from the regression coef-
ficient of the multivariable logistic regression analysis.
Thus, a positive H-FABP bedside-test ‘‘weighted’’ 1.5
points; tachycardia, 2.0 points; and syncope, 1.5 points. By
ROC analysis (AUC, 0.847 [0.746–0.949]) we identified an
optimal cut-off value of 3.0 points for discriminating
between patients with an adverse 30-day outcome and
those with a favourable course. Of 44 patients (32.4 %)
with a score of C3.0 points, 9 patients (20.5 %) developed
complications or died during the first 30 days as opposed to
only two of 92 patients (2.2 %) with a score of \3 points
(p = 0.001). The dichotomised score was associated with a
sensitivity of 82 %, a specificity of 72 %, a PPV of 20 %,
and a NPV of 98 %. Using logistic regression analysis, a
score of C3.0 points was associated with a nearly 12-fold
increase in the risk of an adverse 30-day outcome (OR
11.57 [2.38–56.24]; p = 0.002). The prognostic relevance
of the novel score remained unaffected if adjusted for age
(data not shown). Notably, patients with a score C5.0
points had a 13.7-fold increase in the risk of an adverse
30-day outcome ([3.00–62.69]; p = 0.001) and a rate of an
adverse 30-day outcome of 44.4 % (Fig. 1). Moreover,
increasing points in the score were associated with a con-
tinuous exponential increase in the rate of an adverse
30-day outcome (Fig. 1; p \ 0.001 for trend). Importantly,
none of the 48 patients with a score of 0 points had an
adverse outcome.
Discussion
Detection of an elevated risk amongst normotensive
patients with acute PE remains challenging despite the
large number of studies published in the last decade. As
currently available biomarker assays share the requirement
for time-consuming measurements, the development of
bedside-tests for rapid determination of biomarker con-
centrations appears to be a promising approach. In the
present study, we could demonstrate that bedside testing
for H-FABP is a useful tool for immediate risk stratifica-
tion of normotensive patients with acute PE. Besides the
association of a positive test result with an adverse early
outcome, the H-FABP bedside-test appeared to provide
valuable prognostic information when integrated into a
novel, ‘‘simple’’ clinical score also including tachycardia
and syncope.
H-FABP is a promising biomarker of myocardial injury
with favourable release kinetics [16]. Due to its small
molecular size (15 kDa) and its cytoplasmatic location,
H-FABP plasma concentrations rise as early as 30 min
after the onset of myocardial ischemia, peak at 6–8 h, and
return to normal within 24–30 h [28]. We and others pre-
viously demonstrated that H-FABP is of prognostic value
in patients with acute PE and improves risk stratification of
both unselected and normotensive patients [17–19]. How-
ever, widespread clinical use of H-FABP has been pre-
vented by the need for a time-consuming solid-phase
ELISA. A novel point-of-care test, the CardioDetect lab
assay, allows qualitative determination of H-FABP con-
centrations (positive vs. negative test result) within 20 min
[20]. We could now demonstrate in 136 normotensive
patients with acute PE that the H-FABP bedside-test
Table 3 Predictors of an adverse 30-day outcome
OR 95 % CI p value
H-FABP bedside-test positive 6.98 1.45–33.67 0.016
Tachycardia (HR C100 bpm) 8.28 1.71–40.04 0.009
RV dysfunction 12.23 1.49–100.58 0.020
Syncope 5.05 1.42–17.94 0.012
Displayed are only variables found to significantly predict an adverse
30-day outcome by univariable analysis. ORs with the respective
95 % CI for an adverse 30-day outcome were calculated by logistic
regression analysis
OR odds ratio, CI confidence interval, H-FABP heart-type fatty acid-
binding protein, HR heart rate, bpm beats per minute, RV right
ventricular
Fig. 1 Rate of an adverse 30-day outcome according to the sum of
points in the novel score
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emerged, besides tachycardia, evidence of RV dysfunction
on echocardiography, and syncope, as predictor of an
adverse early outcome.
Multimarker models integrating information obtained
from echocardiography (evidence or exclusion of RV dys-
function) in combination with laboratory biomarkers (such
as growth-differentiation factor-15 (GDF-15) [9], NT-
proBNP [7], cTnT [8, 29]/hsTnT [15], or H-FABP [18, 19])
have been reported to improve risk stratification of acute PE.
This could be confirmed in the present study, in which the
combination of echocardiographic evidence of RV dys-
function with the H-FABP bedside-test predicted a 12.7-fold
increase in the risk of an adverse 30-day outcome. However,
it needs to be kept in mind that echocardiographic criteria
for defining acute RV dysfunction are poorly standardised
and may vary widely between hospitals, ultrasound labora-
tories, and examiners [26, 30]. Moreover, echocardiography
may not be available outside the working hours, especially
in smaller community hospitals. This problem might be
expected to occur even more frequently in normotensive
patients with acute PE, who are generally not considered
‘‘critically ill’’. Therefore, we developed a ‘‘simple’’ clinical
score derived from the significant predictors of an adverse
30-day outcome at univariable logistic regression (excluding
echocardiographic information on RV function). This score
included the H-FABP bedside-test (a positive result was
assigned 1.5 points), tachycardia (heart rate above 100 beats/
min on admission assigned 2 points), and syncope (presence
of syncope assigned 1.5 points). The present score thus
integrates weighed prognostic information from baseline
clinical parameters which are easy to determine in clinical
routine, in combination with a biomarker which can be
measured by a point-of-care test within 20 min. We found
that patients with a score above the calculated cut-off value
of 3.0 points had a 12-fold increase in the risk of an adverse
30-day outcome. In fact, this was nearly identical with the
prognostic information provided by the combination of
echocardiography and the H-FABP bedside-test. Impor-
tantly, none of the 48 patients (35.3 %) with a score of 0 had
an adverse outcome, while two (2.8 %) of the 72 patients
with a negative H-FABP bedside-test and/or normal echo-
cardiogram had an unfavourable course. Further, an
increasing score was associated with a continuous expo-
nential increase in the rate of an adverse 30-day outcome
(Fig. 1). Therefore, calculation of the new score may offer a
valuable and fast alternative for immediate risk assessment
of normotensive patients with acute PE if echocardiography
is not available. Pending external validation of our results,
the novel score might simplify and accelerate risk stratifi-
cation of PE patients in clinical routine in the future.
In the last years, a number of clinical prediction rules
were developed for prognostic assessment of patients with
acute PE. The pulmonary embolism severity index (PESI)
[10] focuses on 11 different weighted patient characteris-
tics such as comorbidities and baseline clinical parameters
and allows stratification into five severity classes. Its sim-
plified version (sPESI) [11] reduces the technical com-
plexity of the original prediction rule by focusing on six
equally weighted variables. However, the (s)PESI, as well
as a score developed by Uresandi et al. [13], appears to be
more suitable for the identification of low-risk patients than
for patients with an elevated risk of an adverse outcome.
The Geneva Score [14] focuses on six different variables
such as comorbidities and haemodynamic parameters but
also needs an ultrasound examination of the leg veins
which may not be available in many hospitals. The PREP
score [31] is based on five different weighted clinical,
echocardiographic [RV/LV ratio), and biochemical vari-
ables (brain natriuretic peptide (BNP)] and allows stratifi-
cation in five severity classes. Another recently proposed
prognostic model consists of NT-proBNP, D-dimer con-
centrations, heart rate, and cancer with a total score range
from 0 to 37 points [12]. The novel score which we
developed in the present study is the first to integrate
baseline clinical parameters and prognostic information
obtained from a cardiac biomarker (in contrast to the
(s)PESI which does not account for right ventricular dys-
function) without the need of a transthoracic echocardio-
gram (as in the PREP score) or ultrasound examination of
the leg veins (as in the Geneva Score). Our score is char-
acterised by low complexity, with only three differently
weighed variables, and by the use of a bedside-test for fast
and immediate risk stratification.
As the purpose of our study was to investigate the per-
formance of the H-FABP bedside-test, we did not compare
it with the quantitative solid-phase enzyme-linked immu-
noadsorbent assay (ELISA) for determination of H-FABP
used in previous studies. Hence, our results may be limited
regarding the universal use of H-FABP values in the novel
score. However, findings from Boscheri et al. [23] indicate
that the CardioDetect lab assay performs as reliably as the
H-FABP ELISA (HyCult biotechnology b.v., Uden, Neth-
erlands). Another limitation is the missing of an external
validation cohort. Thus, the novel score and the application
of the bedside-test require external validation in normo-
tensive patients with acute PE and we are hereby providing
the base of further clinical studies. Moreover, the relatively
small number of events in the acute phase of normotensive
PE is a potential limitation of the present study.
In conclusion, we could demonstrate that the H-FABP
bedside-test reliably identified an increased risk of an
adverse early outcome in a derivation cohort of 136 nor-
motensive patients with acute PE. Importantly, the inte-
gration of the bedside-test into a novel score also including
two baseline clinical parameters, namely tachycardia and
syncope, may offer a simple, readily available and fast
78 Clin Res Cardiol (2013) 102:73–80
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approach to immediate risk assessment of PE, particularly
if imaging of the right ventricle cannot be rapidly obtained.
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